RNS Number : 2701B MaxCyte, Inc. 29 January 2024 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 1340B MaxCyte, Inc. 29 January 2024 MaxCyte announces filing of Form 8-K ROCKVILLE, MD , January 29, 2024 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development
Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer along with additional novel cell therapy programs ROCKVILLE, Md., and SYDNEY, Australia, Jan.
RNS Number : 6275A MaxCyte, Inc. 23 January 2024 MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs Imugene using MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support azer-cel - a potential first-in-class allogeneic CD19
RNS Number : 0139Z MaxCyte, Inc. 09 January 2024 MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results ROCKVILLE, MD , January 9, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
ROCKVILLE, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative
RNS Number : 7228Y MaxCyte, Inc. 05 January 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options and PDMR Dealing ROCKVILLE, MD , 5 January 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies
Lion TCR to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases. ROCKVILLE, Md. and SINGAPORE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading,
RNS Number : 5279Y MaxCyte, Inc. 03 January 2024 MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline Lion TCR to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid
RNS Number : 3554Y MaxCyte, Inc. 02 January 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, MD , January 2 , 2024 - MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
